Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions

Kenichi Suda, Jihye Kim, Isao Murakami, Leslie Rozeboom, Masaki Shimoji, Shigeki Shimizu, Christopher J. Rivard, Tetsuya Mitsudomi, Aik-Choon Tan, Fred R. Hirsch

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Introduction: Data regarding the pre-treatment intertumor heterogeneity of potential biomarkers in advanced-stage lung cancers is limited. A finding of such heterogeneity between primary and metastatic lesions would prove valuable to determine if a metastatic lesion can be a surrogate for the primary tumor, as more biomarkers will likely be used in the future to inform treatment decisions. Methods: We performed RNA sequencing to analyze intertumor heterogeneity in 30 specimens (primary tumors, intrathoracic, and extrathoracic metastatic lesions) obtained from five treatment-naïve lung cancer patients. Results: The global unsupervised clustering analysis showed that the lesions clustered at the individual patient level rather than on the metastatic sites, suggesting that the characteristics of specific tumor cells have a greater impact on the gene expression signature than the microenvironment in which the metastasis develops. The mutational and transcriptional data highlight the presence of intertumor heterogeneity showing that the primary tumors are usually distinct from metastatic lesions. Through a comparison between metastatic lesions and the primary tumors, we observed that pathways related to cell proliferation were upregulated, whereas immune-related pathways were downregulated in metastatic lesions. Conclusion: These data not only provide insight into the evolution of lung cancers, but also imply possibilities and limitations of biomarker-based treatment in lung cancers.

Original languageEnglish
JournalJournal of Thoracic Oncology
DOIs
Publication statusAccepted/In press - 2018 Jan 1
Externally publishedYes

Fingerprint

Spatial Analysis
Molecular Evolution
Lung Neoplasms
Biomarkers
Neoplasms
RNA Sequence Analysis
Therapeutics
Transcriptome
Cluster Analysis
Down-Regulation
Cell Proliferation
Neoplasm Metastasis

Keywords

  • Autopsy
  • Biomarkers
  • Immune-related markers
  • RET fusion
  • RNA sequencing
  • Tumor heterogeneity

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine

Cite this

Suda, K., Kim, J., Murakami, I., Rozeboom, L., Shimoji, M., Shimizu, S., ... Hirsch, F. R. (Accepted/In press). Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions. Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2018.05.039

Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity : Analysis of Treatment-Naïve Lesions. / Suda, Kenichi; Kim, Jihye; Murakami, Isao; Rozeboom, Leslie; Shimoji, Masaki; Shimizu, Shigeki; Rivard, Christopher J.; Mitsudomi, Tetsuya; Tan, Aik-Choon; Hirsch, Fred R.

In: Journal of Thoracic Oncology, 01.01.2018.

Research output: Contribution to journalArticle

Suda, K, Kim, J, Murakami, I, Rozeboom, L, Shimoji, M, Shimizu, S, Rivard, CJ, Mitsudomi, T, Tan, A-C & Hirsch, FR 2018, 'Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Naïve Lesions', Journal of Thoracic Oncology. https://doi.org/10.1016/j.jtho.2018.05.039
Suda, Kenichi ; Kim, Jihye ; Murakami, Isao ; Rozeboom, Leslie ; Shimoji, Masaki ; Shimizu, Shigeki ; Rivard, Christopher J. ; Mitsudomi, Tetsuya ; Tan, Aik-Choon ; Hirsch, Fred R. / Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity : Analysis of Treatment-Naïve Lesions. In: Journal of Thoracic Oncology. 2018.
@article{3c8961d3216540f09a302d6a18d8bd72,
title = "Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity: Analysis of Treatment-Na{\"i}ve Lesions",
abstract = "Introduction: Data regarding the pre-treatment intertumor heterogeneity of potential biomarkers in advanced-stage lung cancers is limited. A finding of such heterogeneity between primary and metastatic lesions would prove valuable to determine if a metastatic lesion can be a surrogate for the primary tumor, as more biomarkers will likely be used in the future to inform treatment decisions. Methods: We performed RNA sequencing to analyze intertumor heterogeneity in 30 specimens (primary tumors, intrathoracic, and extrathoracic metastatic lesions) obtained from five treatment-na{\"i}ve lung cancer patients. Results: The global unsupervised clustering analysis showed that the lesions clustered at the individual patient level rather than on the metastatic sites, suggesting that the characteristics of specific tumor cells have a greater impact on the gene expression signature than the microenvironment in which the metastasis develops. The mutational and transcriptional data highlight the presence of intertumor heterogeneity showing that the primary tumors are usually distinct from metastatic lesions. Through a comparison between metastatic lesions and the primary tumors, we observed that pathways related to cell proliferation were upregulated, whereas immune-related pathways were downregulated in metastatic lesions. Conclusion: These data not only provide insight into the evolution of lung cancers, but also imply possibilities and limitations of biomarker-based treatment in lung cancers.",
keywords = "Autopsy, Biomarkers, Immune-related markers, RET fusion, RNA sequencing, Tumor heterogeneity",
author = "Kenichi Suda and Jihye Kim and Isao Murakami and Leslie Rozeboom and Masaki Shimoji and Shigeki Shimizu and Rivard, {Christopher J.} and Tetsuya Mitsudomi and Aik-Choon Tan and Hirsch, {Fred R.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.jtho.2018.05.039",
language = "English",
journal = "Journal of Thoracic Oncology",
issn = "1556-0864",
publisher = "International Association for the Study of Lung Cancer",

}

TY - JOUR

T1 - Innate Genetic Evolution of Lung Cancers and Spatial Heterogeneity

T2 - Analysis of Treatment-Naïve Lesions

AU - Suda, Kenichi

AU - Kim, Jihye

AU - Murakami, Isao

AU - Rozeboom, Leslie

AU - Shimoji, Masaki

AU - Shimizu, Shigeki

AU - Rivard, Christopher J.

AU - Mitsudomi, Tetsuya

AU - Tan, Aik-Choon

AU - Hirsch, Fred R.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Introduction: Data regarding the pre-treatment intertumor heterogeneity of potential biomarkers in advanced-stage lung cancers is limited. A finding of such heterogeneity between primary and metastatic lesions would prove valuable to determine if a metastatic lesion can be a surrogate for the primary tumor, as more biomarkers will likely be used in the future to inform treatment decisions. Methods: We performed RNA sequencing to analyze intertumor heterogeneity in 30 specimens (primary tumors, intrathoracic, and extrathoracic metastatic lesions) obtained from five treatment-naïve lung cancer patients. Results: The global unsupervised clustering analysis showed that the lesions clustered at the individual patient level rather than on the metastatic sites, suggesting that the characteristics of specific tumor cells have a greater impact on the gene expression signature than the microenvironment in which the metastasis develops. The mutational and transcriptional data highlight the presence of intertumor heterogeneity showing that the primary tumors are usually distinct from metastatic lesions. Through a comparison between metastatic lesions and the primary tumors, we observed that pathways related to cell proliferation were upregulated, whereas immune-related pathways were downregulated in metastatic lesions. Conclusion: These data not only provide insight into the evolution of lung cancers, but also imply possibilities and limitations of biomarker-based treatment in lung cancers.

AB - Introduction: Data regarding the pre-treatment intertumor heterogeneity of potential biomarkers in advanced-stage lung cancers is limited. A finding of such heterogeneity between primary and metastatic lesions would prove valuable to determine if a metastatic lesion can be a surrogate for the primary tumor, as more biomarkers will likely be used in the future to inform treatment decisions. Methods: We performed RNA sequencing to analyze intertumor heterogeneity in 30 specimens (primary tumors, intrathoracic, and extrathoracic metastatic lesions) obtained from five treatment-naïve lung cancer patients. Results: The global unsupervised clustering analysis showed that the lesions clustered at the individual patient level rather than on the metastatic sites, suggesting that the characteristics of specific tumor cells have a greater impact on the gene expression signature than the microenvironment in which the metastasis develops. The mutational and transcriptional data highlight the presence of intertumor heterogeneity showing that the primary tumors are usually distinct from metastatic lesions. Through a comparison between metastatic lesions and the primary tumors, we observed that pathways related to cell proliferation were upregulated, whereas immune-related pathways were downregulated in metastatic lesions. Conclusion: These data not only provide insight into the evolution of lung cancers, but also imply possibilities and limitations of biomarker-based treatment in lung cancers.

KW - Autopsy

KW - Biomarkers

KW - Immune-related markers

KW - RET fusion

KW - RNA sequencing

KW - Tumor heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=85050851702&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050851702&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2018.05.039

DO - 10.1016/j.jtho.2018.05.039

M3 - Article

C2 - 29933065

AN - SCOPUS:85050851702

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

SN - 1556-0864

ER -